Table 2.
Baseline pulmonary function test parameters of patients with ACO by race and ethnicity.
| NHW | AA | Asian | P | |
|---|---|---|---|---|
| (n = 407) | (n = 91) | (n = 373) | ||
| Post-BD FEV1, L | 1.97 ± 0.76 | 1.83 ± 0.72 | 1.75 ± 0.58 | <0.001 |
| Post-BD FEV1, %predicted | 64.6 ± 20.8 | 67.4 ± 18.6 | 58.7 ± 18.4 | <0.001 |
| Post-BD FVC, L | 3.48 ± 1.00 | 3.11 ± 1.01 | 3.40 ± 0.78 | 0.002 |
| Post-BD FVC, %predicted | 86.3 ± 18.0 | 90.1 ± 17.6 | 81.2 ± 16.4 | <0.001 |
| Post-BD FEV1/FVC | 55.9 ± 11.7 | 58.4 ± 10.0 | 51.2 ± 11.9 | <0.001 |
| DLCO, % | 70.3 ± 24.1 | 59.9 ± 20.9 | 64.7 ± 20.4 | <0.001 |
| BDR positivity* | 136 (33.4) | 33 (36.3) | 64 (17.2) | <0.001 |
| Exercise capacity, 6MWD (m) | 419.4 ± 110.2 | 353.5 ± 115.3 | 378.5 ± 111.4 | <0.001 |
Data are presented as the mean ± SD or number (%).
*
Positive bronchodilator response was defined as a post-bronchodilator increase in FEV1 or FVC of at least 12% and 200 ml from baseline values at 15 minutes after inhalation of 400 μg salbutamol.
AA, African American; ACO, asthma–COPD overlap; BD, bronchodilator; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NHW, non-Hispanic white; 6MWD, 6-minute walking distance.